Slide 1: Investor Presentation
Investor Presentation August 29, 2022 Mach7 Technologies ASX: M7T 1
Slide 2: Disclaimer “forward looking” statements
Disclaimer “forward looking” statements Summary of information: This presentation contains general and background information about Mach7 Risks: An investment in M7T securities is subject to investment and other known and unknown risks, Technologies Limited (“M7T”) activities current as at the date
Slide 3: Agenda
Agenda Business Overview FY22 Results Outlook • Our Business • Full-Year Highlights • Our Products • Record Sales Orders • Our Customers – Subscription growth Appendices • Our Global Footprint – New customer acquisition • Our Partners • Record Revenue • Our Value Proposition • Record Recurring Reven
Slide 4: Business Overview
Business Overview Issued 18 February 2021, approved by the Board 4 4
Slide 5: Our Business
Our Business Mach7 – The Enterprise Imaging Solution Mach7’s medical imaging software solution centralises, stores, organises and displays patient data across the healthcare enterprise - connecting hospital networks and facilitating data flow between hospital departments and clinicians everywhere. T
Slide 6: Our Products
Our Products Enterprise Imaging – a focus on the entire healthcare network Mach7 provides an enterprise-wide interoperable platform for storing, retrieving and viewing all medical imaging data in one vendor neutral ecosystem. It comprises: Enterprise Data Management Enterprise Diagnostic Viewing Dep
Slide 7: Our Customers
Our Customers World Market for Radiology IT – Select Product Markets (US$M) Integrated Delivery Independent 3,500 Networks (IDN) Provider Groups 3,000 International hospital authorities Medical Research 2,500 and health systems facilities 2,000 Regional and Telehealth service 1,500 community hospita
Slide 8: Our Global Footprint
Our Global Footprint >150 Customers 15 Countries Australia Canada China France Hong Kong Indonesia Italy Netherlands Qatar Philippines Singapore Saudi Arabia Hospital United Kingdom systems around United States the world use Mach7 Vietnam Technologies 8
Slide 9: Our Partners
Our Partners Partnerships focused on Partnerships represent 8% of Mach7’s FY22 sales orders Meaningful Value to Support Patient Care Augmenting and expanding Mach7’s Enterprise Imaging Solution through innovative partnerships designed to enhance value to healthcare providers. 27 partnership solution
Slide 10: Our Value Proposition
Our Value Proposition Fits Individual Needs Designed for the Enterprise Flexible Workflows We can fit into customers’ existing The foundation is in the enterprise, not Flexibility of workflows – with an intuitive technology infrastructure or adapt as it individual departmental systems. The Mach7 and
Slide 11: Our Revenue Model
Our Revenue Model Revenue model caters to client funding needs Flexible revenue model allows for both subscription (“SaaS”) and capital licences, generally on 5-year terms. Equivalent Contracts: Capital Licence Subscription Licence Activity/Timing Fee Type Revenue Contribution Revenue Contribution R
Slide 12: FY22 Results
FY22 Results Issued 18 February 2021, approved by the Board 12 12
Slide 13: Full Year Highlights
Full Year Highlights Annual Recurring Record Sales Order Contracted Annual Revenue (ARR) growth (TCV)1 Record Revenue Recurring $13.4M recognised $33.2M $27.1M Revenue (CARR) +$2.5M or 23% PCP +$7.6M or 30% PCP2 +$8.1M or 42% PCP $17.3M $14.4M run rate +$1.5M or 9.5% PCP +$1M or 7.5% PCP Net Operati
Slide 14: Record Sales Orders – Subscription Growth
Record Sales Orders – Subscription Growth Recurring revenue an increasing component of sales orders Highlights: Total Sales Orders (TCV in Constant Currency) • Record sales orders of $33.2M (TCV), up 30% on $25.6M in Sales Orders by Type FY21 (+26% constant currency). Sales orders are the best 35 me
Slide 15: Record Sales Orders – New Customer Acquisition
Record Sales Orders – New Customer Acquisition New customers set the stage for further growth Highlights: Sales Order Composition by Order Type • New customer sales orders of $17.9M (54% of total sales 20 orders) representing 10 new customers. Expect new $17.9 customers to account for a similar leve
Slide 16: Record Revenue
Record Revenue Highlights: FY 2022 FY 2021 % Change • Record revenue of $27.1M, up 42% on $19.0M in FY21 Enterprise Diagnostic 10.7 M 7.5 M 43% (+37% constant currency) Viewing (eUnity) Enterprise Data 16.4 M 11.5 M 42% • Pricing uplift on licence renewals Management (VNA)1 • VNA pricing up 10% annu
Slide 17: Record Recurring Revenue
Record Recurring Revenue Recurring revenue growth Highlights: • Contracted Annual Recurring Revenue (CARR) of $17.3M, up Recurring Revenue: CARR v ARR 9.5% on $15.8M in FY21. CARR is the lead indicator for ARR – the 20 $2.9M difference to ARR run rate ($14.4M) represents time lag for software going
Slide 18: Significant Contract Wins
Significant Contract Wins Satisfied customers expand into Mach7’s product suite Highlights: • Trinity Health - $7.4M (TCV) subscription to Mach7 Platform, Diagnostic Viewer and Worklist as an add-on to eUnity solution. Deployment to be staged in 6 waves across 92 hospitals in 22 states. Wave 1 ($0.9
Slide 19: Strong Financials
Strong Financials EBITDA positive, cashflow positive, healthy cash balance, no debt Earnings FY22 FY21 % Change Highlights: Revenues 27.1M 19.0 M +42% • Scalable business with revenues growing faster than expenses, ($8.1M or 42% revenue growth, Distributor Fees 1.0 M 0.6M +64% compared with $4.8M or
Slide 20: Outlook
Outlook Business as usual Customers are Award-winning Strong sales tech spend resumes prioritising spend products pipeline Hospitals are emerging Inflation pressures are seeing Highly acclaimed Experienced sales team from COVID crisis hospitals prioritise spending. products translating leveraging op
Slide 21: Contact Us
Contact Us Investor Relations, Mach7: Rebecca Thompson +61 (0) 416 079 329 Rebecca.Thompson@mach7t.com Investor Relations: Simon Hinsley, NWR Communications +61 (0) 401 809 653 simon@nwrcommunications.com.au Registered Office: Level 4 | 100 Albert Road, South Melbourne, VIC Issued 18 February 2021,
Slide 22: Appendices
Appendices Issued 18 February 2021, approved by the Board 22 22
Slide 23: Mach7 Global network
Mach7 Global network More than 150 customers spanning 15 countries Hospitals and healthcare entities around the world deploy Mach7’s solutions and innovative technologies. We have built a global network of diverse customers that range from expansive Integrated Delivery Networks, National Health Syst
Slide 24: KLAS – Defined
KLAS – Defined The Best in KLAS report recognizes software and services companies who excel in helping healthcare professionals improve patient care. KLAS surveys’ healthcare IT customers (providers) throughout Best in KLAS is highly competitive and the calendar year and releases its final findings
Slide 25: Our Industry Position
Our Industry Position Best in KLAS Best in KLAS CIO 2022 Report 2022 Report Bulletin #2 #3 50 Most Influential Companies of the Year 2022 Industry Performer Industry Performer Published in April 2022 Universal Viewer Vendor Neutral Archive 25
Slide 26: Mach7 Performance
Mach7 Performance Best in KLAS 2022 - VNA Mach7 springs out of Limited Data #3 segment to #3 in performance “Solution Comparison” listing. Mach7 goes from 7 to 18 distinct site survey respondents showing significantly increased customer engagement and attachment. Outperforming similar size and type
Slide 27: Mach7 Performance
Mach7 Performance Best in KLAS 2022- Universal Viewer #2 Vaulted to #2 overall ranking in Market #1 Held the #1 spot for most of CY 2021 Currently in #1 rank in live #1 data in KLAS Notable performance is a 95% 95% score for “Would you buy again.” Industry average is 84% 27
Slide 28: Reasons Customers Love Mach7
Reasons Customers Love Mach7 Innovation Expertise Relationships We have grown from a culture Our development and We pride ourselves on forming of innovation. We believe in integration team consists of lasting partnerships with each of taking a fresh look at our pioneers in the field of healthcare ou
Slide 29: Experienced Leadership Team
Experienced Leadership Team Mike Lampron Steve Parkes Lisa Thompson Ravi Krishnan Chief Executive Officer Global Chief Financial Officer Vice President, Services General Manager, APAC Bob Tranchida David Madaffri Andrew Volkening 29 Vice President, Marketing Global Vice President, Sales Vice Preside
Slide 30: Our Board of Directors
Our Board of Directors David Chambers Mike Lampron Eliot Siegel, MD Non-Executive Chairman Managing Director Non-Executive Director We have grown from a culture of innovation. We believe in taking a fresh look at our industry and challenges, in learning from our customers, and in improving patient c
Slide 31: Corporate Overview
Corporate Overview Corporate Snapshot $1.20 1.8 ASX Code M7T ' 12-month share price performance 1.6 Share Price (26 August 2022) $0.65 $1.00 1.4 Market Capitalisation (26 August 2022) $155M $0.80 1.2 Shares on Issue 239M 1.0 $0.60 0.8 $0.40 0.6 We have grown from a culture Substantial Shareholders o